Lastly, research by Scuderi et al. [80] introduced a potential therapeutic angle by demonstrating that the chemical compound BX795, a selective inhibitor of PDK1 (pyruvate dehydrogenase kinase1), significantly reduced SOX3 expression in various glioblastoma cell lines, pointing to the targeting of SOX3 pathways as a promising approach to improve disease outcomes [80] (Table 1). The gene discussed is SOX3; the disease is glioblastoma.